Form 4: IMMUNIC, INC. Director Acquires Stock Options

IMMUNIC, INC. reports that Director Jon Congleton acquired 25,370 stock options on July 5, 2026, as part of a vesting schedule.

Summary

• Director Jon Congleton was granted 25,370 stock options with an exercise price of $14.80.
• The options were acquired on July 5, 2026, and are set to expire on July 5, 2036.
• These options vest in monthly increments over one year from the grant date.
• Following this transaction, Congleton beneficially owns 25,370 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Director Jon Congleton's acquisition of stock options indicates a commitment to the company's future performance.
• The vesting schedule over one year suggests a long-term incentive aligned with company growth.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value and long-term company success.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially incentivizing actions that could increase share value over the long term.

Key Dates

Keywords

IMMUNIC, INC., IMUX, Form 4, Stock Options, Director, Beneficial Ownership, Securities, SEC Filing